Back to news

TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™

Business Wire•18/11/2026•07:30 ET
0

Key Highlights

  • ➤TG Therapeutics ranked No. 5 on Deloitte Technology Fast 500.
  • ➤Three-year growth was fueled by BRIUMVI revenues.
  • ➤BRIUMVI received U.S. approval for relapsing multiple sclerosis in December 2022.
  • ➤Recognition marks TG Therapeutics’ third consecutive year on the list.

Expert Statements

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics

“We are proud to be once again recognized as one of the fastest-growing companies in North America on the Deloitte Technology Fast 500 list. This recognition reflects the unwavering commitment of our incredible team and the strong success in bringing BRIUMVI to people with relapsing forms of multiple sclerosis. As we continue our mission to develop and provide treatment alternatives for those in need, we are grateful for the trust and support we have received from the multiple sclerosis community.”

TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™

Third Year in a Row, Named as One of the Fastest-Growing Companies in North America

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in